Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Endocrinology and Nephropathy, Weihai Hospital, Weihai, China.
Front Endocrinol (Lausanne). 2022 Jul 11;13:938830. doi: 10.3389/fendo.2022.938830. eCollection 2022.
Diabetic kidney disease (DKD) causes the greatest proportion of end-stage renal disease (ESRD)-related mortality and has become a high concern in patients with diabetes mellitus (DM). Bone is considered an endocrine organ, playing an emerging role in regulating glucose and energy metabolism. Accumulating research has proven that bone-derived hormones are involved in glucose metabolism and the pathogenesis of DM complications, especially DKD. Furthermore, these hormones are considered to be promising predictors and prospective treatment targets for DM and DKD. In this review, we focused on bone-derived hormones, including fibroblast growth factor 23, osteocalcin, sclerostin, and lipocalin 2, and summarized their role in regulating glucose metabolism and DKD.
糖尿病肾病（DKD）导致终末期肾病（ESRD）相关死亡率的比例最大，已成为糖尿病患者的高度关注。骨骼被认为是内分泌器官，在调节葡萄糖和能量代谢方面发挥着新兴作用。越来越多的研究证明，骨源性激素参与葡萄糖代谢和糖尿病并发症的发病机制，尤其是 DKD。此外，这些激素被认为是糖尿病和 DKD 的有前途的预测指标和潜在治疗靶点。在这篇综述中，我们重点介绍了骨源性激素，包括成纤维细胞生长因子 23、骨钙素、硬骨素和脂联素 2，并总结了它们在调节葡萄糖代谢和 DKD 中的作用。
